CVT-301 (levodopa inhalation powder) improves Patient Global Impression of Change (PGIC) over 1 year in patients with Parkinson’s disease (PD): a meta-analysis
Objective: A meta-analysis of PGIC results was performed using combined data from 3 different studies of CVT-301 in patients with PD over a total of…Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease
Objective: Utilize clinical trial data to analyze amantadine delayed release/extended release (AMT DR/ER) capsules as an early add-on for OFF and dyskinesia in people with…Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results
Objective: To implement home-based monitoring (HBM) using wearable devices, a smartphone dedicated app and patient reported outcomes in order to provide a more comprehensive picture…Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients With Motor Fluctuations and Dyskinesia Managed With Oral Dopaminergic Therapies Versus Device-Aided Therapies
Objective: To compare clinical outcomes of patients with Parkinson's disease (PD) with moderate and severe motor fluctuations or dyskinesia managed with oral dopaminergic medications vs…Indirect Treatment Comparison of Adjunctive Treatments for Patients with Parkinson’s Disease Experiencing Motor Complications
Objective: Evaluate the comparative efficacy of treatment options for Parkinson's disease (PD) motor complications using indirect treatment comparison. Background: Amantadine delayed release/extended release (DR/ER) capsules…Influence of Dopamine Transporter Gene Polymorphism on Wearing Off
Objective: To study the influence of Dopamine transporter gene polymorphism on Wearing off (WO) through 19 items wearing off questionnaire (WOQ-19) Background: The dopamine transporter…Analysis of Amantadine formulations for OFF and Dyskinesia in Parkinson Disease
Objective: Evaluate the effects of amantadine formulations on the treatment of OFF and dyskinesia in Parkinson’s patients. Background: There are currently three formulations of amantadine…Levodopa/carbidopa intestinal gel (LCIG) reduces fluctuations and shortens time to on without troublesome dyskinesia in advanced Parkinson’s Disease: Post-hoc analyses of 54-week LCIG-monotherapy trial
Objective: To assess the long-term effectiveness of LCIG monotherapy on reducing daily health-state fluctuations and time to on without troublesome dyskinesia (ONwoTD) after waking Background:…Safinamide Improves Pain in Parkinson´s Disease. Results from the SAFINONMOTOR Study.
Objective: Our aim was to analyze the effectiveness of safinamide on pain in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…Prevalence, impact, and factors associated with excessive buccal saliva in the COPARK database
Objective: To describe the prevalence of sialorrhea and drooling in Parkinson’s Disease (PD) patients of the COPARK study, to find factors associated to these conditions,…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 26
- Next Page »